$28.09
5.61% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US00973Y1082
Symbol
AKRO

Akero Therapeutics Inc Stock price

$28.09
-1.84 6.15% 1M
+7.02 33.32% 6M
+4.74 20.30% YTD
+13.44 91.74% 1Y
+2.16 8.33% 3Y
+8.61 44.20% 5Y
+12.09 75.56% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-1.67 5.61%
ISIN
US00973Y1082
Symbol
AKRO

Key metrics

Market capitalization $1.96b
Enterprise Value $1.28b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.65
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-269.27m
Free Cash Flow (TTM) Free Cash Flow $-211.64m
Cash position $717.25m
EPS (TTM) EPS $-3.75
P/E forward negative
Short interest 5.64%
Show more

Is Akero Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Akero Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Akero Therapeutics Inc forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Akero Therapeutics Inc forecast:

Buy
89%
Hold
11%

Financial data from Akero Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.01 0.01
95% 95%
-
-0.01 -0.01
95% 95%
-
- Selling and Administrative Expenses 38 38
29% 29%
-
- Research and Development Expense 232 232
117% 117%
-
-269 -269
98% 98%
-
- Depreciation and Amortization 0.01 0.01
95% 95%
-
EBIT (Operating Income) EBIT -269 -269
97% 97%
-
Net Profit -237 -237
98% 98%
-

In millions USD.

Don't miss a Thing! We will send you all news about Akero Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Akero Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about 10 hours ago
-- Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of three orthogonal measures: (1) ≥1-stage fibrosis improvement by NASH-CRN stage (conventional histopathology), (2) 30% reduction of liver stiffness by FibroScan ® (imaging fibrosis biomarker), and (3) 0.5 point decrease in ELF TM score (serum fibrosis biomar...
Neutral
GlobeNewsWire
2 days ago
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 1...
Neutral
GlobeNewsWire
8 days ago
— First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to MASH —
More Akero Therapeutics Inc News

Company Profile

Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

Head office United States
CEO Andrew Cheng
Employees 56
Founded 2017
Website www.akerotx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today